Antisense therapy restores fragile X protein production in human cells
Science Daily: Pharmacology News
JULY 5, 2023
An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome.
Science Daily: Pharmacology News
JULY 5, 2023
An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome.
Broad Institute
MARCH 22, 2024
Messenger RNAs with multiple “tails” could lead to more effective therapeutics By Corie Lok March 22, 2024 Breadcrumb Home Messenger RNAs with multiple “tails” could lead to more effective therapeutics Scientists have engineered long lasting mRNAs that increased therapeutic protein production in cells and animals. and Virginia W.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
MAY 14, 2024
William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. coli polymerase produce the corresponding RNA at the same time as the bacteria produced its own RNA and proteins. “I coli genome and let the E.
Sygnature Discovery
SEPTEMBER 12, 2024
Cell Science Commercial and in-house modified E. coli strains for well folded proteins. Protein Purification Standard chromatography methods for purification of high grade protein. In vivo biotinylation of target protein. Dedicated Membrane protein production team. Low endotoxin batches.
Broad Institute
JUNE 29, 2023
Each colored dot in a vast RIBOmap readout represents one mRNA molecule as it is being used to produce the corresponding protein — a process called translation. By Sarah C.P. Williams June 29, 2023 Credit: Zeng H, Huang J, Ren J, et al. and Virginia W. Paper cited Zeng, H. Spatially resolved single-cell translatomics at molecular resolution.
Drug Target Review
OCTOBER 10, 2023
I and our team are committed to delivering high-quality, custom recombinant proteins and antibodies, and we look forward to partnering with researchers and industry leaders worldwide to forge a brighter future in the life sciences.” “The The company specialises in recombinant protein production and antibody development.
Sygnature Discovery
SEPTEMBER 11, 2024
We’ve successfully tackled targets for: Unprecedented membrane proteins Intrinsically disordered proteins Refolding from inclusion bodies Large protein complexes Labelled proteins for NMR studies RNA structures by crystallography Across our capabilities Protein Expression & Purification Vast diversity of proteins produced.
Let's personalize your content